In Vivo is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Biomarkers: Shaking Up--and Protecting--the World's Biggest Drug Market

Executive Summary

The ASTEROID trial for Crestor, showing that it's the first statin known to reduce arterial plaque, has shaken up the $20 billion statin business, showing how biomarkers-not clinical endpoints-can dramatically shift share in even well established markets. And while the news was largely bad for beleaguered Lipitor, the trial's reaffirmation of the importance of potency also shows why the coming generics won't significantly hurt the market leaders.
Advertisement

Related Content

Pfizer's Analyst Day: And Now, For Its Next Trick

Topics

Related Companies

Related Deals

Advertisement
UsernamePublicRestriction

Register

IV002743

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel